Although currently unavailable in China, PI3K and AKT inhibitors have shown potential to improve prognosis in HR+/HER2- BC patients with activation of the PI3K/AKT/mTOR pathway, providing an alternative strategy to overcome endocrine resistance (7, 9, 15). This evidence concerns the gene ERBB2 and breast cancer.